GILD

#86
Gilead Sciences, Inc. - Common Stock
134.4 3 USD
-0.85%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
134.41
134.48
년간 변동
104.46
157.27
일일 변동
-0.85%
월간 변동
+5.06%
6달 변화
+6.95%
년간 변동율
+20.44%
이전 종가
135.5 8
Open
134.4 8
저가
134.4 1
High
134.4 8
양
640
전체 차트 열기 Full chart

Financials

개요 성명 통계 배당금
4분기 연간
  • Market Capitalization 166.9 B
  • Employee 17 K
  • Founded 1987
  • CEO Daniel O'Day
  • Website www.gilead.com
  • Headquarter Delaware, United States
  • FIGI BBG000CKGBP2
  • Industry 종합 의약품 제조업체
총매출
순이익
주당 순이익(기본 EPS)
총부채
잉여 현금 흐름
현금 및 현금성 자산
주가수익비율
18.96
주가매출액비율
5.88
주당 배당금
0.82
배당수익률 %
3.99

Gilead Sciences, Inc. - Common Stock

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. It has recently expanded into different therapeutic areas such as oncology and inflammation. Gilead is a member of the Nasdaq-100 and the S&P 100. Gilead was founded in 1987 under the name Oligogen by Michael L. Riordan. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs like Tamiflu and Vistide that decade. In the 2000s, Gilead received approval for drugs including Viread and Hepsera, among others. It began evolving from a biotechnology company into a pharmaceutical company, acquiring several subsidiaries, though it still relied heavily on contracting to manufacture its drugs. The company continued its growth in the 2010s.

뉴스